Compare GSK plc (GSK) vs HCA Health Inc (HCA) Price & Performance

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

HCA Healthcare trades at $413.27, down 0.18% on the day, with strong technical momentum showing a bullish moving average signal. The company reported solid Q2 2026 earnings with EPS of $7.59 beating estimates of $7.56, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $75.60 billion, while maintaining healthy profit margins of 8.77%. Recent management appointments and ongoing legal investigations create mixed sentiment around the stock.

HCA presents a compelling value opportunity with attractive valuation multiples (P/E 13.8, EV/EBITDA 8.8) and strong analyst support (63% buy ratings, $449.93 price target). However, investors face risks from multiple ongoing legal investigations, high debt levels (debt-to-asset ratio 80.9% in 2025), and margin pressure from rising operational costs. The stock offers 8.9% upside to consensus target but requires monitoring of legal developments and expense management.